Literature DB >> 25868749

Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands.

Kevin Trujillo1, Silvia Paoletta1, Evgeny Kiselev1, Kenneth A Jacobson2.   

Abstract

The P2Y14 receptor (P2Y14R) is a Gi protein-coupled receptor that is activated by uracil nucleotides UDP and UDP-glucose. The P2Y14R structure has yet to be solved through X-ray crystallography, but the recent agonist-bound crystal structure of the P2Y12R provides a potentially suitable template for its homology modeling for rational structure-based design of selective and high-affinity ligands. In this study, we applied ligand docking and molecular dynamics refinement to a P2Y14R homology model to qualitatively explain structure-activity relationships of previously published synthetic nucleotide analogues and to probe the quality of P2Y14R homology modeling as a template for structure-based design. The P2Y14R model supports the hypothesis of a conserved binding mode of nucleotides in the three P2Y12-like receptors involving functionally conserved residues. We predict phosphate group interactions with R253(6.55), K277(7.35), Y256(6.58) and Q260(6.62), nucleobase (anti-conformation) π-π stacking with Y102(3.33) and the role of F191(5.42) as a means for selectivity among P2Y12-like receptors. The glucose moiety of UDP-glucose docked in a secondary subpocket at the P2Y14R homology model. Thus, P2Y14R homology modeling may allow detailed prediction of interactions to facilitate the design of high affinity, selective agonists as pharmacological tools to study the P2Y14R. Published by Elsevier Ltd.

Entities:  

Keywords:  Docking; G protein-coupled receptor; Homology modeling; P2Y(14) receptor; Uracil nucleotides

Mesh:

Substances:

Year:  2015        PMID: 25868749      PMCID: PMC4468048          DOI: 10.1016/j.bmc.2015.03.042

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  43 in total

1.  Studies on the structure of the G-protein-coupled receptor rhodopsin including the putative G-protein binding site in unactivated and activated forms.

Authors:  P L Yeagle; G Choi; A D Albert
Journal:  Biochemistry       Date:  2001-10-02       Impact factor: 3.162

Review 2.  Molecular modeling as a tool to investigate molecular recognition in P2Y receptors.

Authors:  Stefano Moro; Kenneth A Jacobson
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

3.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure.

Authors:  Tetsuji Okada; Minoru Sugihara; Ana-Nicoleta Bondar; Marcus Elstner; Peter Entel; Volker Buss
Journal:  J Mol Biol       Date:  2004-09-10       Impact factor: 5.469

4.  Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference.

Authors:  Stefano Costanzi; Bhalchandra V Joshi; Savitri Maddileti; Liaman Mamedova; Maria J Gonzalez-Moa; Victor E Marquez; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

5.  Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges.

Authors:  K Vanommeslaeghe; E Prabhu Raman; A D MacKerell
Journal:  J Chem Inf Model       Date:  2012-11-28       Impact factor: 4.956

6.  Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor.

Authors:  Francesca Deflorian; Kenneth A Jacobson
Journal:  J Comput Aided Mol Des       Date:  2011-04-03       Impact factor: 3.686

7.  Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups.

Authors:  Arijit Das; Hyojin Ko; Lauren E Burianek; Matthew O Barrett; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

8.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles.

Authors:  Robert B Best; Xiao Zhu; Jihyun Shim; Pedro E M Lopes; Jeetain Mittal; Michael Feig; Alexander D Mackerell
Journal:  J Chem Theory Comput       Date:  2012-07-18       Impact factor: 6.006

9.  The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.

Authors:  Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

10.  Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation.

Authors:  Chiara Bianca Maria Platania; Salvatore Salomone; Gian Marco Leggio; Filippo Drago; Claudio Bucolo
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

View more
  11 in total

1.  Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y₁₄ receptor.

Authors:  Evgeny Kiselev; Ramachandran Balasubramanian; Elisa Uliassi; Kyle A Brown; Kevin Trujillo; Vsevolod Katritch; Eva Hammes; Raymond C Stevens; T Kendall Harden; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2015-08-10       Impact factor: 2.823

Review 2.  Medicinal chemistry of adenosine, P2Y and P2X receptors.

Authors:  Kenneth A Jacobson; Christa E Müller
Journal:  Neuropharmacology       Date:  2015-12-12       Impact factor: 5.250

Review 3.  Nucleotides Acting at P2Y Receptors: Connecting Structure and Function.

Authors:  Kenneth A Jacobson; Silvia Paoletta; Vsevolod Katritch; Beili Wu; Zhan-Guo Gao; Qiang Zhao; Raymond C Stevens; Evgeny Kiselev
Journal:  Mol Pharmacol       Date:  2015-04-02       Impact factor: 4.436

Review 4.  Polypharmacology of conformationally locked methanocarba nucleosides.

Authors:  Kenneth A Jacobson; Dilip K Tosh; Kiran S Toti; Antonella Ciancetta
Journal:  Drug Discov Today       Date:  2017-08-03       Impact factor: 7.851

5.  Structure-Guided Modification of Heterocyclic Antagonists of the P2Y14 Receptor.

Authors:  Jinha Yu; Antonella Ciancetta; Steven Dudas; Sierra Duca; Justine Lottermoser; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2018-05-16       Impact factor: 7.446

Review 6.  New paradigms in GPCR drug discovery.

Authors:  Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2015-08-08       Impact factor: 5.858

Review 7.  Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  ChemMedChem       Date:  2020-09-18       Impact factor: 3.540

8.  Nucleoside 5'-O-monophosphorothioates as modulators of the P2Y14 receptor and mast cell degranulation.

Authors:  Edyta Gendaszewska-Darmach; Edyta Węgłowska; Aurelia Walczak-Drzewiecka; Kaja Karaś
Journal:  Oncotarget       Date:  2016-10-25

9.  Structure-activity relationships of pyrimidine nucleotides containing a 5'-α,β-methylene diphosphonate at the P2Y6 receptor.

Authors:  Paola Oliva; Mirko Scortichini; Clemens Dobelmann; Shanu Jain; Varun Gopinatth; Kiran S Toti; Ngan B Phung; Anna Junker; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2021-05-26       Impact factor: 2.940

10.  Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists.

Authors:  Anna Junker; Ramachandran Balasubramanian; Antonella Ciancetta; Elisa Uliassi; Evgeny Kiselev; Chiara Martiriggiano; Kevin Trujillo; Giorgi Mtchedlidze; Leah Birdwell; Kyle A Brown; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2016-06-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.